Podcasts about othman laraki

In the ever-evolving landscape of technology and entrepreneurship, few stories are as multifaceted and inspiring as that of Othman Laraki. This interview dives into Othman's story, offering a deep exploration of the world of building, scaling, and transforming companies. Othman relates his experiences working in healthcare and artificial intelligence and eventually building Color Health. This venture has attracted funding from top-tier investors like General Catalyst Partners, Viking Global Investors, Emerson Collective, and T. Rowe Price.

Color Health is delivering care programs in the public and private sectors that vertically integrate disparate workflows to drive outcomes for all stakeholders, cofounder and CEO Othman Laraki tells Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Laraki sits down with BI analyst Jonathan Palmer for a discussion on the company's pivot to health delivery, the challenges facing self-insured employers, its partnership with the American Cancer Society and why fee-for-service shouldn't be a dirty word. See omnystudio.com/listener for privacy information.

The U.S. healthcare market isn't exactly known for its efficiency. A quarter of every dollar spent on healthcare in the U.S. covers the transaction itself, and the market frequently limits consumers to a handful of choices. Othman Laraki, CEO of Color Health, joins Justin to share his vision of a more free and open healthcare market with less friction, lower costs, and greater access. Othman and Justin discuss how underutilization of preventive care amplifies expenses downstream, whether decoupling health insurance and clinical networks can improve access, and why efforts on the margins can go a long way toward eliminating friction across the care continuum.Justin and Othman also brush off their macroeconomics textbooks to examine the market from an academic perspective: Do current payment models manufacture scarcity? Might other industries' markets offer a positive model for healthcare? And can increased competition keep the market from swallowing the value we put into it? This discussion is literally one for the books. To learn more about Definitive Healthcare, please visit us at definitivehc.com.

Color spun up huge COVID testing sites overnight to slow the pandemic. Now it's got a $4.6B valuation and is working on making genomics, vaccines, antivirals, and more accessible to the masses. Color founder and CEO Othman Laraki joins PressClub to discuss the little things that make a big difference in population health, and how we can be better prepared for the next pandemic.Listen in to learn:How Color launched 13K COVID test sites when the government hesitatedWhy laughably ambitious healthcare initiatives now seem feasibleHow economic subsidies for bad food are making Americans sickWhat will unlock improvements in heart, cancer, and mental health careWhat's still broken in healthcare, from insurance to doctor burnoutWhy making healthcare convenient is our next big challengeThis PressClub will make you see we're all in it togetherSubscribe to PressClub at http://constine.club/. This podcast is recorded live on Josh Constine's PressClub on Clubhouse, Thursdays at 4pm PT. PressClub is Clubhouse's first show, where the big names in tech discuss the big ideas. It's hosted by Josh Constine, an investor at early-stage venture fund SignalFire and the former Editor-At-Large of TechCrunch. PressClub is a relaxed venue where luminaries can share their stories, passions, thoughts on trends, and visions of the future. Past guests on PressClub include the founders of Facebook, Instagram, Slack, Shopify, Spotify, Substack, WordPress, Patreon, and more. Thanks for being part of our futurist community!

Othman Laraki, CEO of Color Health, discusses how private healthcare companies can work with public groups to improve access to care. We hear about investing in early-stage life sciences and health-tech companies from Youssef Sebban, Managing Partner at Eckuity. Bloomberg Entertainment Reporter, Kelly Gilblom, gives an update on the "Top Gun: Maverick" opening weekend. And we Drive to the Close with Jack Murphy, Portfolio Manager and Co-CIO at Easterly Investment Partners. Hosted by Carol Massar and Tim Stenovec. Producer: Paul Brennan. See omnystudio.com/listener for privacy information.

Othman Laraki, CEO of Color Health, discusses how private healthcare companies can work with public groups to improve access to care. We hear about investing in early-stage life sciences and health-tech companies from Youssef Sebban, Managing Partner at Eckuity. Bloomberg Entertainment Reporter, Kelly Gilblom, gives an update on the "Top Gun: Maverick" opening weekend. And we Drive to the Close with Jack Murphy, Portfolio Manager and Co-CIO at Easterly Investment Partners. Hosted by Carol Massar and Tim Stenovec. Producer: Paul Brennan. See omnystudio.com/listener for privacy information.

Join us in the BreakLine Arena for a conversation with Othman Laraki, CEO and Co-Founder of Color.Othman and his team are building Color to support durable and equitable public health across entire populations. Color's technology and clinical services are the backbone of large-scale population health programs for over 200 institutions worldwide, with data and services spanning hereditary cancers, heart disease, infectious disease testing (including COVID-19), and community-based vaccination programs. Previously, Othman served as a VP of Product Management at Twitter and was an early Product Management pioneer at Google. He shared his stunning career in the tech industry, how diversity is the key to disrupting an industry for the better, and how his personal experience growing up in Morocco, emigrating to the US, and helping to build top tech companies led him to found Color.If you like what you hear, please like, rate, or review our show! We'd love to hear your thoughts. If you're interested in joining our community, please visit www.breakline.org.

Othman Laraki, CEO of Color Health, discusses the national Covid testing and vaccine landscape as well as new funding for the health technology startup. Bloomberg News Washington Bureau Chief Peggy Collins talks about Federal Reserve Governor Lael Brainard interviewing for the top job at the U.S. central bank. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Real Estate Reporter Patrick Clark share Patrick's Businessweek Magazine story Zillow's Algo-Fueled Buying Spree Sank Home-Flipping Experiment. Bloomberg Opinion Columnist Brooke Sutherland reports on General Electric announcing a split into three separate companies in a stunning breakup of the iconic manufacturer. And We Drive to the Close with Jessica Bemer, Portfolio Manager at Easterly Investment Partners Hosts: Carol Massar and Katie Greifeld. Producer: Paul Brennan. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Othman Laraki, CEO of Color Health, discusses the national Covid testing and vaccine landscape as well as new funding for the health technology startup. Bloomberg News Washington Bureau Chief Peggy Collins talks about Federal Reserve Governor Lael Brainard interviewing for the top job at the U.S. central bank. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Real Estate Reporter Patrick Clark share Patrick's Businessweek Magazine story Zillow's Algo-Fueled Buying Spree Sank Home-Flipping Experiment. Bloomberg Opinion Columnist Brooke Sutherland reports on General Electric announcing a split into three separate companies in a stunning breakup of the iconic manufacturer. And We Drive to the Close with Jessica Bemer, Portfolio Manager at Easterly Investment Partners Hosts: Carol Massar and Katie Greifeld. Producer: Paul Brennan. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Othman Laraki is the co-founder and CEO of Color, a distributed healthcare and clinical testing company. From population genomics programs to high-throughput COVID-19 testing, Color provides the technology and infrastructure to power large-scale health initiatives. In this conversation with Stanford lecturer Toby Corey, Laraki discusses the genesis of Color, the immense challenges and opportunities in the healthcare sector, and Color's race into COVID testing when the pandemic hit.

Othman Laraki is the co-founder and CEO of Color, a distributed healthcare and clinical testing company. From population genomics programs to high-throughput COVID-19 testing, Color provides the technology and infrastructure to power large-scale health initiatives. In this conversation with Stanford lecturer Toby Corey, Laraki discusses the genesis of Color, the immense challenges and opportunities in the healthcare sector, and Color’s race into COVID testing when the pandemic hit.

What if you could discover what diseases you're genetically predisposed for? That's the problem Othman Laraki set out to solve at Color, with a tech-forward approach to genomics. Since launching in 2013, Color's aim has expanded to building public health infrastructure (making it no surprise that Color is one of San Francisco's biggest Covid-19 test providers). With degrees from Stanford and MIT and tech experience from Twitter and Google, Othman is bringing an outsider's view to healthtech. Othman shares why entrepreneurship requires a level of irrationality, why a minimalistic UI is critical in healthcare, and how he defines Color's customers.

In this episode of Health Stories, Erik is talking to Othman Laraki (@othman) and Alicia Zhou (@ay_zhou) of Color. Othman is co-founder and CEO and Alicia Zhou is Head of Research. Othman explains the personal reason that he started Color and why he got involved in the healthcare space after previously working at Google and running a company that was acquired by Twitter.Alicia and Othman explain the advances Color has made in genomics and how the approach they’re taking is different from that of other companies in the space. You might not have known that 30% of your health is related to your genome. There are also a number of new types of care that can be unlocked by having your genome sequenced.Othman explains how at Color they are hoping to follow the model of Google or Amazon where early in the company’s life they focus on doing one thing really well, then expand into other areas. He also talks about where he would be building a company in the space if he wasn't working at Color as well as where he might look to invest. They also discuss the time Othman wore a glucose monitor full-time and how it changed how he thinks about health, why he is hoping for an “iPhone moment” in the healthcare space, and why the future of cancer treatment will be much more about prevention than treatment.Thanks for listening — if you like what you hear, please review us on your favorite podcast platform. Check us out on the web at villageglobal.vc or get in touch with us on Twitter @villageglobal.Venture Stories is brought to you by Village Global and is hosted by co-founder and partner, Erik Torenberg. Colin Campbell is our audio engineer and the show is produced by Brett Bolkowy.

In this episode of Health Stories, Erik is talking to Othman Laraki (@othman) and Alicia Zhou (@ay_zhou) of Color. Othman is co-founder and CEO and Alicia Zhou is Head of Research. Othman explains the personal reason that he started Color and why he got involved in the healthcare space after previously working at Google and running a company that was acquired by Twitter.Alicia and Othman explain the advances Color has made in genomics and how the approach they’re taking is different from that of other companies in the space. You might not have known that 30% of your health is related to your genome. There are also a number of new types of care that can be unlocked by having your genome sequenced.Othman explains how at Color they are hoping to follow the model of Google or Amazon where early in the company’s life they focus on doing one thing really well, then expand into other areas. He also talks about where he would be building a company in the space if he wasn't working at Color as well as where he might look to invest. They also discuss the time Othman wore a glucose monitor full-time and how it changed how he thinks about health, why he is hoping for an “iPhone moment” in the healthcare space, and why the future of cancer treatment will be much more about prevention than treatment.Thanks for listening — if you like what you hear, please review us on your favorite podcast platform. Check us out on the web at villageglobal.vc or get in touch with us on Twitter @villageglobal.Venture Stories is brought to you by Village Global and is hosted by co-founder and partner, Erik Torenberg. Colin Campbell is our audio engineer and the show is produced by Brett Bolkowy.

Produced by Foundersuite.com, "How I Raised It" goes behind the scenes with startup founders who have raised capital. This episode is with Yin Wu of DirtProtocol.com. Dirt Protocol is using blockchain technology to create a new approach to verify information. The Company raised $3 million of seed funding from Digital Currency Group, Caffeinated Capital and SV Angel on July 11, 2018. Village Global, ZhenFund, General Catalyst, Greylock Partners, Hustle Fund, INBlockchain, Lightspeed Venture Partners, Avichal Garg, Liquid 2 Ventures, Danhua Capital, Vy Capital, Divergence Digital Currency Fund and Pantera Capital also participated in the round along with 11 angel investors, including Elad Gil and Othman Laraki. In this episode, Yin talks about curating trust in the crypto and ICO space, identifying the top blockchain investors, stacking investor conversations in an optimal way, how to get an investor's "greed to overcome their fear" when pitching a new market, and much more.

The Sunday Times tech correspondent Danny Fortson brings on Othman Laraki, founder of Color Genomics, to talk about taking genomics to masses by reducing the cost by an order of magnitude (4:45), the importance of genetic counselling (6:45), the ‘value for money’ equation (12:35), how data is treated (14:55), starting the company after leaving Twitter (20:35), the slow evolution of genomics’ role in consumer health (23:00), how these tests may be abused by insurers (25:50), raising $150m (28:45), the coming healthcare revolution (31:15), and choosing treatable diseases (34:20). PLUS: Ellen Matloff, a genetic counselor and founder of My Gene Counsel, to talk about whether ignorance is bliss (36:40), the danger of misdiagnosis (38:25), why consumer genetics is here to stay (41:20), and why your genetic data may already be in a company’s hands (43:00). See acast.com/privacy for privacy and opt-out information.

CNBC's Chrissy Farr talks with Othman Laraki, Co-founder & CEO of gene testing company Color Genomics, about advances in genetic testing, gene counciling, and what the future holds in the field with commentary by CB Insights Digital Health Analyst, Nikhil Krishnan.

The post E796: Othman Laraki, Color CEO & Co-founder, uses genetics to engage people in preventative health & early disease detection, draws on deep experience as entrepreneur, investor & carrier of BRCA gene appeared first on This Week In Startups.

During this week’s episode of STACK That, we dive into the world of data and machine learning in healthcare. We sat down with Othman Laraki from Color Genomics, a company that’s making major strides into mapping the human genome and helping the medical world build better solutions for discovering predispositions to disease.

DNA Analysis for Common Cancers is the topic. Color.com founder Othman Laraki describes how his company can help determine your risk for common hereditary cancers Pponsored by Refillwise,com. Text the word DREW to 22822 and see what you can save today.

Aneesh Chopra, the United States’ first Chief Technology Officer under President Barack Obama, sat down with Color’s CEO and co-founder Othman Laraki, to discuss the intersection between data and healthcare.

Recode Decode: Doctors should think like mechanics (Othman Laraki, CEO, Color) by Best Of Tech & Startups

Color Genomics co-founder and CEO Othman Laraki talks with Recode's Kara Swisher about why we're on the verge of a healthcare revolution. Laraki, whose company tests buyers' genes for certain hereditary cancers, says the future of medicine will be defined by our ability to read data from our bodies. While most of that data used to be recorded on paper and stored at hospitals, now it's largely being generated and stored on our smartphones; he predicts that to achieve truly personalized medicine, we will need artificially intelligenct software that can comb this data, changing the role of doctors in the process. Learn more about your ad choices. Visit megaphone.fm/adchoices

The O'Reilly Radar Podcast: Color Genomics, genetic testing access, and the future of precision medicine.This week, I chat with Othman Laraki, co-founder of Color Genomics. We chat about challenges and opportunities in genetic testing, the future of precision medicine, and the hurdles medicine and health care are currently facing (and how we can overcome them).Here are some highlights: Genetics testing for everyone Genetics, we felt, had come to a point where there was an opportunity to have a very big impact by essentially mixing some of the best of the biology world with software—in many ways, genetics had started to become, in part, a software problem. It felt like it was starting to be possible to build products that made genetics accessible to a much broader population by both dropping costs as well as increasing access, so making this information more accessible to a much broader population in a scalable way. ... For example, one of the things we did that we're very proud of is we created this program called the Every Woman Program, where whenever someone buys a test from Color, they can also contribute to fund testing for someone who can't afford it. Then we work with a number of cancer centers, for example at UCSF and the University of Washington, Morehouse in Georgia, and a number of others, where each one of those centers works with underprivileged populations, and they can provide tests for free for people who can't afford it but who the doctors think should get tested. Opportunities in machine learning One of the big opportunities for machine learning in genetics, for example, is around the interpretation of the effects of specific genetic changes. Right now, there are set of guidelines or processes that are used by the industry around the interpretation of how a specific mutation impacts a gene. It's a structured process that's very labor intensive, but it's one of those areas where over time is going to become something that's very heavily solved by machine learning because there's a lot of data that can be used to train a model instead of purely running it in a manual way. The industry is going to evolve quite a bit over the next few years and machine learning is going to have very substantial impact there. Using the full data set of the human body Each one of us is carrying and generating a tremendous amount of data in our daily lives, whether it's our genome, our microbiome, etc., etc. So far, the link between that data and health practice had been through the path of research and translation to a few proxies, essentially, where researchers collect a lot of data, they do a research study, it turns into a set of conclusions, and that over time gets turned into a few rules that get introduced into medical practice. If someone's lipid levels are at this level, etc., then you draw these kinds of conclusions. Now, we're coming to the point where the amount of data that a doctor will be able to use in a real way to make medical decisions is going to be the full data set of our bodies, which is very exciting and can have a very big impact. Long-tail distribution of genetic insights In some ways, I feel right now we've come to this point where there's been enough data and science behind us that we can already create a lot of value, and that allows the bootstrapping of doing things at a massive scale that really takes us to that long-tail distribution of insights around how genetics work and how the body works.

The O'Reilly Radar Podcast: Color Genomics, genetic testing access, and the future of precision medicine.This week, I chat with Othman Laraki, co-founder of Color Genomics. We chat about challenges and opportunities in genetic testing, the future of precision medicine, and the hurdles medicine and health care are currently facing (and how we can overcome them).Here are some highlights: Genetics testing for everyone Genetics, we felt, had come to a point where there was an opportunity to have a very big impact by essentially mixing some of the best of the biology world with software—in many ways, genetics had started to become, in part, a software problem. It felt like it was starting to be possible to build products that made genetics accessible to a much broader population by both dropping costs as well as increasing access, so making this information more accessible to a much broader population in a scalable way. ... For example, one of the things we did that we're very proud of is we created this program called the Every Woman Program, where whenever someone buys a test from Color, they can also contribute to fund testing for someone who can't afford it. Then we work with a number of cancer centers, for example at UCSF and the University of Washington, Morehouse in Georgia, and a number of others, where each one of those centers works with underprivileged populations, and they can provide tests for free for people who can't afford it but who the doctors think should get tested. Opportunities in machine learning One of the big opportunities for machine learning in genetics, for example, is around the interpretation of the effects of specific genetic changes. Right now, there are set of guidelines or processes that are used by the industry around the interpretation of how a specific mutation impacts a gene. It's a structured process that's very labor intensive, but it's one of those areas where over time is going to become something that's very heavily solved by machine learning because there's a lot of data that can be used to train a model instead of purely running it in a manual way. The industry is going to evolve quite a bit over the next few years and machine learning is going to have very substantial impact there. Using the full data set of the human body Each one of us is carrying and generating a tremendous amount of data in our daily lives, whether it's our genome, our microbiome, etc., etc. So far, the link between that data and health practice had been through the path of research and translation to a few proxies, essentially, where researchers collect a lot of data, they do a research study, it turns into a set of conclusions, and that over time gets turned into a few rules that get introduced into medical practice. If someone's lipid levels are at this level, etc., then you draw these kinds of conclusions. Now, we're coming to the point where the amount of data that a doctor will be able to use in a real way to make medical decisions is going to be the full data set of our bodies, which is very exciting and can have a very big impact. Long-tail distribution of genetic insights In some ways, I feel right now we've come to this point where there's been enough data and science behind us that we can already create a lot of value, and that allows the bootstrapping of doing things at a massive scale that really takes us to that long-tail distribution of insights around how genetics work and how the body works.